107447-04-1Relevant articles and documents
Synthesis of a new inhibitor of breast cancer resistance protein with significantly improved pharmacokinetic profiles
Li, Yuexian,Woo, Jiyeon,Chmielecki, Jessica,Xia, Cindy Q.,Liao, Mingxiang,Chuang, Bei-Ching,Yang, Johnny J.,Guan, Miao Y.,Plesescu, Mihaela,Prakash, Shimoga R.
, p. 551 - 555 (2016/01/09)
The design, synthesis, in vitro inhibitory potency, and pharmacokinetic (PK) profiles of Ko143 analogs are described. Compared to commonly used Ko143, the new breast cancer resistance protein (BCRP) inhibitor (compound A) showed the same potency and a sig
INHIBITOR OF BREAST CANCER RESISTANCE PROTEIN (BCRP)
-
, (2015/04/28)
Disclosed are compounds that inhibit breast cancer resistance protein (BCRP), of which compound (I-1), ((3S, 6S, 12aS)-6-isobutyl-9-methoxy-3-methyl-2,3,6,7, 12, 12a- hexahydropyrazino[1',2': 1,6]pyrido[3,4-b]indole-1,4-dione) or a pharmaceutically accept
Synthetic Approaches to Fumitremorgins. III. Synthesis of Optically Active Pentacyclic Ring Systems, and Their Oxidation at Ring C
Nakagawa, Masako,Fukushima, Hiroshi,Kawate, Tomohiko,Hongu, Mitsuya,Une, Teruaki,et al.
, p. 23 - 32 (2007/10/02)
Pictet-Spengler reaction of L-tryptophan methyl ester (9) and 6-methoxy-L-tryptophan methyl ester (40) with isovaleraldehyde (10) in methylene chloride in the presence of trifluoroacetic acid gave the cis-tetrahydro-β-carboline (11, 41) as the major isome